Catheter Precision, Inc. (VTAK)

Catheter Precision, Inc. (VTAK) Healthcare & Pipeline Overview

Catheter Precision, Inc. specializes in electrophysiology solutions, offering technologies like the View into Ventricular Onset System for 3D cardiac mapping. Targeting idiopathic ventricular arrhythmias, the company provides tools for hospitals and physicians in the U.S., positioning itself within the competitive medical device landscape focused on cardiac care.

What Is the Investment Thesis for VTAK?

Catheter Precision presents a focused play on the electrophysiology market, driven by its VIVO system for 3D cardiac mapping. The company's small size and specialized product line offer potential for high growth if VIVO gains traction in the market. A key value driver is the potential for increased adoption of VIVO in EP procedures, improving localization of ventricular arrhythmias. However, the company's negative profit margin of -2381.1% and limited financial resources pose significant risks. Successful commercialization and market penetration are critical for the company's long-term viability. Investors should monitor adoption rates of VIVO and the company's ability to secure additional funding to support its operations.

Based on FMP financials and quantitative analysis

VTAK Key Highlights

• Market Cap of $1.45M reflects its status as a micro-cap company.
• P/E ratio of -1.03 indicates the company is currently not profitable.
• Profit Margin of -2381.1% highlights significant losses relative to revenue.
• Gross Margin of 20.3% shows some profitability at the product level before operating expenses.
• Beta of -0.16 suggests the stock is less volatile than the overall market.

Who Are VTAK's Competitors?

VTAK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VTAK's Key Strengths?

• Proprietary VIVO system for 3D cardiac mapping.
• Focus on a specific niche within electrophysiology.
• Experienced management team.
• Established relationships with key hospitals and physicians.

What Are VTAK's Weaknesses?

• Limited financial resources.
• Negative profit margin.
• Small market capitalization.
• Dependence on a limited number of products.

What Could Drive VTAK Stock Higher?

• Increased adoption of the VIVO system by hospitals and cardiology centers.
• Positive clinical trial results demonstrating the efficacy of VIVO.
• Expansion of sales and marketing efforts in the United States.
• Potential partnerships with larger medical device companies.
• Development of next-generation cardiac mapping technology.

What Are the Key Risks for VTAK?

• Financial-distress signal — its Altman Z-Score of -14.55 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from larger medical device companies with greater resources.
• Limited financial resources and negative profit margin.
• Technological obsolescence of existing products.
• Regulatory changes impacting the approval and sale of medical devices.
• Dependence on a limited number of products for revenue.

What Are the Growth Opportunities for VTAK?

• Expansion of VIVO System Adoption: Catheter Precision can drive growth by increasing the adoption of its VIVO system among electrophysiologists. The market for cardiac mapping systems is growing, driven by the increasing prevalence of cardiac arrhythmias. Securing partnerships with major hospitals and cardiology centers could significantly boost VIVO's market penetration. Timeline: Ongoing, with continuous efforts to educate and train physicians on the benefits of VIVO.
• Development of Next-Generation Mapping Technology: Investing in research and development to create next-generation cardiac mapping technology can provide a competitive edge. This could involve incorporating AI and machine learning to improve the accuracy and efficiency of mapping procedures. Timeline: 3-5 years for development and regulatory approval.
• Geographic Expansion: Expanding sales and marketing efforts beyond the United States could unlock new markets for Catheter Precision's products. Europe and Asia represent significant opportunities for growth, given the increasing prevalence of cardiac arrhythmias globally. Timeline: 2-3 years to establish distribution networks and regulatory approvals in key international markets.
• Strategic Partnerships and Acquisitions: Forming strategic partnerships with larger medical device companies or acquiring complementary technologies could accelerate growth. This could provide access to new markets, distribution channels, and product portfolios. Timeline: Ongoing, with continuous evaluation of potential partnership and acquisition opportunities.
• Expanding Product Portfolio: Catheter Precision can expand its product portfolio by developing new devices and solutions for cardiac arrhythmia treatment. This could include catheters, ablation systems, and diagnostic tools. A broader product offering would allow the company to capture a larger share of the electrophysiology market. Timeline: 3-5 years for development and regulatory approval of new products.

What Opportunities Does VTAK Have?

• Increasing adoption of VIVO system.
• Expansion into new geographic markets.
• Development of next-generation mapping technology.
• Strategic partnerships and acquisitions.

What Threats Does VTAK Face?

• Competition from larger medical device companies.
• Technological obsolescence.
• Regulatory changes.
• Economic downturn.

What Are VTAK's Competitive Advantages?

• Proprietary 3D cardiac mapping technology with the VIVO system.
• Specialized product line focused on electrophysiology.
• Established relationships with key hospitals and physicians in the U.S.
• Patents and intellectual property protecting its technology.

What Does VTAK Do?

Catheter Precision, Inc., formerly known as Ra Medical Systems, Inc., rebranded in August 2023 to reflect its sharpened focus on electrophysiology. The company develops and delivers products designed to improve the lives of patients with cardiac arrhythmias. Its flagship product, the View into Ventricular Onset System (VIVO), provides non-invasive 3D cardiac mapping, aiding in the localization of idiopathic ventricular arrhythmias in patients with structurally normal hearts before electrophysiology (EP) procedures. This technology aims to enhance the precision and effectiveness of these procedures. In addition to VIVO, Catheter Precision offers LockeT, a suture retention device, and the Amigo Remote Catheter System, a robotic arm designed to serve as a catheter control device. These products complement their core mapping technology, providing a suite of tools for electrophysiologists. Based in Fort Mill, South Carolina, Catheter Precision targets the U.S. market, focusing on hospitals and physicians specializing in cardiac arrhythmia treatment. The company's evolution reflects a strategic shift towards specialized medical devices within the broader healthcare sector.

What Products and Services Does VTAK Offer?

• Develops and delivers electrophysiology products.
• Offers the View into Ventricular Onset System (VIVO) for 3D cardiac mapping.
• Provides LockeT, a suture retention device.
• Offers the Amigo Remote Catheter System, a robotic arm for catheter control.
• Focuses on improving the treatment of cardiac arrhythmias.
• Targets patients, hospitals, and physicians in the United States.
• Specializes in technologies and solutions for cardiac electrophysiology.

How Does VTAK Make Money?

• Sales of the View into Ventricular Onset System (VIVO) to hospitals and cardiology centers.
• Sales of LockeT suture retention devices.
• Sales of the Amigo Remote Catheter System.
• Providing training and support services for its products.

What Industry Does VTAK Operate In?

Catheter Precision operates in the medical device industry, specifically within the electrophysiology segment. This segment is characterized by technological innovation and increasing demand for minimally invasive procedures. The market is competitive, with established players and emerging companies vying for market share. Catheter Precision's focus on 3D cardiac mapping positions it within a niche area of the market, targeting improved precision in arrhythmia treatment. The company's success depends on its ability to differentiate its products and gain adoption among electrophysiologists.

Who Are VTAK's Key Customers?

• Hospitals and cardiology centers in the United States.
• Electrophysiologists and cardiologists.
• Patients with cardiac arrhythmias.

FY2026 estForward Outlook

Wall Street analysts project Catheter Precision, Inc. revenue of about $10.2M for fiscal 2026, with EPS near $-60.80.

F-Score 3/9Financial Health

Catheter Precision, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.55 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -42.3%, showing how much profit it generates from its asset base. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -0.9%, the inverse of the P/E and a quick read on earnings relative to price.

Catheter Precision, Inc. (VTAK) Valuation Context

Valued at $1.45M, VTAK is classified as a micro-cap stock. Relative to its peer group, VTAK's quantitative score of 17/100 is below the peer average of 71/100.

Company Profile

Catheter Precision, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Fort Mill, US. The company is led by CEO David A. Jenkins. VTAK has traded publicly since 2018.

VTAK Financials

VTAK Latest News

VTAK Analyst Consensus

VTAK MoonshotScore

Latest Catheter Precision, Inc. Analysis

VTAK Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources